Before prescribing tirzepatide, a provider evaluates whether the patient has contraindications, checks for drug interactions, establishes baseline bloodwork, and creates a monitoring plan for side effects
Competing strictly on medication pricing against heavily funded tech companies is a losing battle for newer brands
It's not always the case but it does come to mind
The headline On Thursday 21 May 2026, Eli Lilly announced that participants in TRIUMPH-1, the first Phase 3 trial of retatrutide in obesity, lost an average of 28.3% of their body weight at 80 weeks on the 12 mg dose, with 45.3% losing at least 30% of their starting weight [1]
Providers determine whether compounded formulations or alternative treatment pathways are appropriate for each patient
378 A small clinical trial involving 18 patients with IBS found adhering to personalized food restrictions based on reactions to food reintroductions after a short-term low-FODMAP diet resulted in lasting symptom relief after one year in 12 of the participants
